Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06113809 · ClinicalTrials.gov registry record · Phase 1
Palbociclib and Pembrolizumab in Sarcoma
A Phase 1 study of Sarcoma, sponsored by John Rieth.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT06113809: Recruiting Phase 1 study of Sarcoma, sponsored by John Rieth.
NCT06113809 is a Phase 1 study of Sarcoma that is actively recruiting participants, run by John Rieth. The registered enrollment target is 8 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06113809, a Phase 1 study of Sarcoma, is actively recruiting participants, sponsored by John Rieth.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-arm open-label window of opportunity clinical study assessing the impact of pre-treatment with palbociclib in patients with soft tissue sarcomas for which PD-1 inhibitors are approved (includes undifferentiated pleomorphic sarcoma, myxofibrosarcoma, angiosarcoma, pleomorphic rhabdomyosarcoma, pleomorphic liposarcoma, or alveolar soft part sarcoma).
Primary Outcome
Confirm the safety of the combination of Palbociclib and pembrolizumab in sarcomas for which PD-1 inhibitors are approved as defined by the incidence of DLTs
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Palbociclib
Study Locations (1)
Iowa
- University of Iowa Hospitals & Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2028-07 |
| Phase | Phase 1 |
What NCT06113809 shows while recruiting
NCT06113809 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06113809 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT06113809 about?
NCT06113809 is a clinical study titled "Palbociclib and Pembrolizumab in Sarcoma". This is a single-arm open-label window of opportunity clinical study assessing the impact of pre-treatment with palbociclib in patients with soft tissue sarcomas for which PD-1 inhibitors are approved (includes undifferentiated pleomorphic sarcoma, myxofibrosarcoma, angiosarcoma, pleomorphic rhabdom...
What is the current status of trial NCT06113809?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-02-01. Estimated completion is 2028-07.
What conditions does trial NCT06113809 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT06113809?
The interventions under investigation include: Pembrolizumab (DRUG), Palbociclib (DRUG).
Who is sponsoring clinical trial NCT06113809?
This trial is sponsored by John Rieth, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06113809 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06113809's enrollment target sits among peer trials
8 119th of 122 higher than 3 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
-
A Study of CRD3874-SI in People With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy